Shares of Organon & Co (NYSE:OGN) jumped in aftermarket trading Thursday evening after a report said India-based Sun Pharmaceutical Industries Ltd. (NSE:SUN) was preparing a $13 billion binding offer for the women's health-focused company.
Organon rose as much as 8% in after-hours trade, reaching above $9.20 per share. The company had a reported market capitalization of $2.2 billion as of the close on Thursday.
The report said Sun Pharma planned to present an all-cash bid that would be fully financed by JP Morgan, MUFG and Citi, citing people familiar with the matter. According to the same report, Sun intends to fold Organon into its existing operations and does not plan to issue Sun shares to Organon shareholders as part of the transaction.
Recent accounts have suggested that Sun Pharma and Germany's Gruenthal were both potential suitors for Organon, with both companies looking to expand their positions in women’s health. Observers have also cited Organon’s U.S. manufacturing footprint as an attractive element of the target.
Context on investor tools cited in the report
The published coverage that prompted the market move referenced investor tools and services that evaluate acquisition candidates and broader equities. One service mentioned uses AI-driven strategies to screen companies across many financial metrics and has cited past winners such as Super Micro Computer (+185%) and AppLovin (+157%) as part of its highlighted performance history.
The same suite of commentary framed a question about whether investors should consider new positions in Sun Pharma at a given dollar amount, noting that the system evaluates companies across fundamentals, momentum and valuation without human bias.
What is clear and what remains uncertain
- The aftermarket share increase for Organon followed a media report that Sun Pharma is preparing a $13 billion binding all-cash offer.
- The reported financing for the proposed bid is from JP Morgan, MUFG and Citi, and the plan reportedly would see Organon incorporated into Sun’s operations without Sun issuing its own shares to Organon stakeholders.
- Competing interest from another potential buyer, Gruenthal, has been reported, and Organon’s U.S. manufacturing capabilities have been singled out as a valuable asset.
At this stage the developments described are based on reported plans and coverage that influenced after-hours trading activity. Further confirmation, formal filings or official statements would be required to move the situation beyond the status of competing reports and market reactions.